CRIS DEMO – Liste Projekte IZKF

Darstellung von Forschungsprojekten einer Organisation, Angabe orgID, Akkordion

cris show=projects orgID=105831630 format=accordion

Term: September 1, 2020 - June 30, 2024
Funding source: DFG-Einzelförderung / Sachbeihilfe (EIN-SBH)
Project leader:

Colorectal carcinoma (CRC) is one of the most challenging diseases world-wide, causing deaths of hundreds of thousands of people yearly. In our previous work we showed that ITGB6 expression and serum levels are increased in metastatic stages of CRC. Moreover, ITGB6 serum levels were found to be associated with therapy response and functional studies in CRC mouse models suggested that pharmacologic ITGB6 inhibition may counteract tumor growth. Here we aim to elucidate the role of ITGB6 as a pathogenic…

→ More information

Term: May 1, 2022 - April 30, 2023
Funding source: Volkswagen Stiftung
Project leader:

Immune checkpoint inhibitors (ICIs) have revolutionized classical approaches to the treatment of various cancer entities, but are also associated with a number of side effects. One of these may be life-threatening clotting disorders with risk of thrombotic or hemorrhagic complications, the mechanisms of which are still poorly understood. In the present study, we analyze the direct effects of pembrolizumab, nivolumab and ipilimumab on platelet aggregation as well as plasma coagulation followed by fibrinolysis in an ex vivo model.

→ More information

Term: June 1, 2024 - May 31, 2025
Funding source: Bayerische Staatsministerien
Project leader:

→ More information

Term: February 16, 2017 - December 31, 2020
Funding source: DFG / Forschungsgruppe (FOR)
Project leader: ,

→ More information

Term: July 1, 2018 - June 30, 2022
Funding source: DFG / Sonderforschungsbereich / Transregio (SFB / TRR)
Project leader:

Das Blutgefäßsystem besitzt eine entscheidende Barrierefunktion bei chronisch entzündlichen Darmerkrankungen (CED). IFN-Ƴ ist ein wichtiger Pathogenesefaktor bei CED mit signifikanter Wirkung auf Blutgefäße. Im Projekt sollen die molekularen Mechanismen aufgeklärt werden über die eine IFN-Ƴ-vermittelte Aktivierung der Gefäßendothelzellen, die vaskuläre Barrierefunktion und die Interaktion von Immun- und Epithelzellen im Rahmen der CED-Pathogenese beeinträchtigt. Dieser Ansatz soll langfristig …

→ More information

Term: January 1, 2018 - June 30, 2026
Funding source: DFG / Sonderforschungsbereich / Transregio (SFB / TRR)
Project leader:

Das Blutgefäßsystem besitzt eine entscheidende Barrierefunktion bei chronisch entzündlichen Darmerkrankungen (CED). IFN-Ƴ ist ein wichtiger Pathogenesefaktor bei CED mit signifikanter Wirkung auf Blutgefäße. Im Projekt sollen die molekularen Mechanismen aufgeklärt werden über die eine IFN-Ƴ-vermittelte Aktivierung der Gefäßendothelzellen, die vaskuläre Barrierefunktion und die Interaktion von Immun- und Epithelzellen im Rahmen der CED-Pathogenese beeinträchtigt. Dieser Ansatz soll langfristig …

→ More information

Term: May 1, 2025 - December 31, 2027
Funding source: Stiftungen
Project leader:

→ More information

Term: January 1, 2023 - December 31, 2027
Project leader:

→ More information

Term: January 1, 2002 - December 31, 2010
Funding source: DFG / Schwerpunktprogramm (SPP)
Project leader:

→ More information

Term: October 1, 2025 - June 30, 2029
Funding source: DFG / Sonderforschungsbereich / Transregio (SFB / TRR)
Project leader:

→ More information

Term: October 1, 2025 - June 30, 2029
Funding source: DFG / Sonderforschungsbereich / Transregio (SFB / TRR)
Project leader:

→ More information

Term: October 1, 2011 - October 31, 2014
Funding source: DFG / Klinische Forschungsgruppe (KFO)
Project leader:

Inflammatory bowel diseases (IBD) are characterized by two important cell biological features, namely T-cell activation and angiogenesis. In this framework Interferon (IFN)-y is regarded as an important regulatory molecule of immune function and T-cell activation. Vascular endothelial growth factor is known as a major angiogenesis factor. Based on previous results of our group, the project focuses on two new and complementary functions of both of these major pathogenesis factors in IBD, namely…

→ More information

Term: October 1, 2025 - June 30, 2029
Funding source: DFG / Sonderforschungsbereich / Transregio (SFB / TRR)
Project leader: ,

The matricellular protein SPARCL1 which is expressed preferentially in tumor vessel endothelial cells (TEC) of CRCs with a Th1-like TME, acts as angiocrine repressor of tumorigenesis by stabilizing vessels, inhibiting angiogenesis and tumor cell proliferation. Employing a vessel-specific knockout of SPARCL1 (SPARCL1ΔIECKO). The project will determine the impact of TEC plasticity on lipid metabolism and ferroptosis and their role for therapy response, including standard chemotherapy, targeted …

→ More information

Term: March 1, 2012 - February 28, 2015
Funding source: Deutsche Krebshilfe
Project leader: ,

→ More information

Term: September 16, 2018 - June 30, 2020

The tumor microenvironment (TME) plays a pivotal role in tumorigenesis, prognosis and therapy. SPARCL1 is a vascular derived anti-tumorigenic factor that counteracts CRC tumorigenesis in a TME-dependent manner. Preliminary results indicate that SPARCL1 regulates ERK phosphorylation and subcellular localization in endothelial and CRC cells. This project aims to elucidate the signaling pathways by which SPARCL1 transmits its anti-proliferative and anti-angiogenic functions, mainly focusing on ERK.

→ More information

Term: June 1, 2009 - May 31, 2011
Funding source: EU - 7. RP / People / Intra-European Fellowship for Career Development (IEF)
Project leader:

The human guanylate binding protein-1 (hGBP-1) characterizes inflammatory cytokine (IC)-activated blood vessel endothelial cells (EC) and regulates the antiangiogenic activity of IC in these cells in vitro and in vivo. In addition, hGBP-1 is the first GTPase which has been observed to be secreted. In colorectal carcinoma, the expression of hGBP-1 in the tumour stroma has been shown in a recent work to be an independent prognostic factor associated with a better outcome. The project focuses on…

→ More information

Term: April 1, 2023 - March 31, 2026
Funding source: DFG-Einzelförderung / Sachbeihilfe (EIN-SBH)
Project leader:

→ More information

Term: January 1, 2018 - December 31, 2021
Project leader:

→ More information

Term: March 1, 2021 - February 28, 2022
Project leader:

Aim of the proposed study is the definition of an independent parameter for the diagnostic evaluation of the perfusion situation of the calf muscle based on MSOT-method in a cross-sectional collective of healthy volunteers and patients with different stages of PAVK (study group 1). The validation of the results will be performed by an independent validation group (study group 2).

→ More information

Term: April 1, 2025 - March 31, 2026
Project leader:

We present a project that aims to characterize the pediatric enteric nervous system (ENS) based on analyses of pediatric intestinal tissue, blood and stool. The interaction between the microbiome and the ENS in children will be focused as well as its influence on immunological responses. The complex processes of the pediatric microbiome-gut-brain axis have not yet been investigated and might be crucial in the pathogenesis of other diseases.

→ More information

Term: October 1, 2019 - March 31, 2024
Funding source: EU - 8. Rahmenprogramm - Horizon 2020
Project leader:

→ More information

Term: January 1, 2019 - December 31, 2024
Funding source: andere Förderorganisation
Project leader:

→ More information

Term: August 1, 2009 - July 31, 2013
Funding source: Bundesministerium für Forschung, Technologie und Raumfahrt (BMFTR)
Project leader:

→ More information

Term: January 1, 2021 - December 31, 2028
Funding source: DFG / Sonderforschungsbereich / Transregio (SFB / TRR)
Project leader: ,

In Deutschland leben mehr als 4 Millionen Patienten mit der Diagnose "Krebs". Für viele von ihnen konnte eine lokale Krankheitskontrolle erreicht werden und sie leben unter dem Damoklesschwert des drohenden Rückfalls, d.h. der metachronen Metastasierung. Späte Fernrezidive zeigen jedoch, dass gestreute Krebszellen (DCCs) lange Zeit außerhalb des Primärtumors überleben und die Fähigkeit behalten, zu wachsen und Metastasen zu bilden. Doch welche Mechanismen sind während der klinischen Latenzzeiten wirksam…

→ More information

Term: January 1, 2016 - September 30, 2024
Funding source: DFG / Forschungsgruppe (FOR)
Project leader: ,

Colorectal cancer (CRC) is among the major death-causing cancers worldwide. Exploiting cellular memory processes of cultivated tumor endothelial cells (TEC), we identified SPARCL1 as a marker of tumor microenvironment (TME)-dependent plasticity of TEC in CRC. In tissues, SPARCL1 was highly expressed in mature, quiescent vessels in normal colon and CRC with a Th1-TME but down-regulated in CRC with non-Th1-TME and worse prognosis. In culture, SPARCL1 expression was induced in endothelial cells…

→ More information

Term: January 1, 2013 - December 31, 2017
Funding source: DFG / Sonderforschungsbereich (SFB)
Project leader: ,

Nekroptose ist eine über spezifische zelluläre Programme ablaufende Nekrose, die durch einen zellulären Proteinkomplex, das Ripoptosom, reguliert wird. Zelluläre FLIP-Proteine sind zentrale Regulatoren der Ripoptosomaktivität. Bestimmte Viren kodieren ebenfalls für FLIP-homologe Moleküle. Im Rahmen des geplanten Projekts soll die Bedeutung des von Kaposi Sarkom-assoziierten Herpesvirus kodierten viralen FLIP für Nekroptose und Ripoptosombildung an Zellkulturmodellen, Tiermodellen und humanen…

→ More information

Term: September 1, 2007 - May 6, 2011
Funding source: DFG-Einzelförderung / Sachbeihilfe (EIN-SBH)
Project leader:

→ More information